Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Immunotherapy With ex Vivo Expanded Haploidentical Natural Killer Cells for Children/Young Adults With High-risk, Refractory or Relapsed AML

NCT05272293 is registered in ClinicalTrials.gov with Belarusian Research Center for Pediatric Oncology, Hematology and Immunology as lead sponsor.

NCT NCT05272293
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05272293 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Immunotherapy With ex Vivo Expanded Haploidentical Natural Killer Cells for Children/Young Adults With High-risk, Refractory or Relapsed AML
Lead sponsor
Belarusian Research Center for Pediatric Oncology, Hematology and Immunology
Phase
Phase 1/2
Overall status
Recruiting
Start date
November 1, 2021
Completion date
June 30, 2026
Enrollment
15 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia